Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kropf

Showing results (831-840 of 862) with videos related to

Pageof 87
Sort By:
Hypertension (Dallas, Tex. : 1979)|December 28, 2017
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing AdenomaBritta Heinze, Carmina T Fuss, Paolo Mulatero, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
EMBO Molecular Medicine|March 5, 2015
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myelomaKathrin Philipp-Abbrederis, Ken Herrmann, Stefan Knop, et al.
ESC Heart Failure|July 15, 2022
Peak O<sub>2</sub> -pulse predicts exercise training-induced changes in peak V̇O<sub>2</sub> in heart failure with preserved ejection fractionStephan Mueller, Bernhard Haller, Anna Feuerstein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasmsBrady L Stein, Jason Gotlib, Murat Arcasoy, et al.
Science Translational Medicine|December 6, 2023
Intervertebral disc human nucleus pulposus cells associated with back pain trigger neurite outgrowth in vitro and pain behaviors in ratsWensen Jiang, Juliane D Glaeser, Giselle Kaneda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2022
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with GuadecitabineCasey L O'Connell, Maria R Baer, Andreas Due Ørskov, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)ValidationJulie Farand, Jeffrey E Kropf, Peter Blomgren, et al.
Pageof 87

Showing results (831-840 of 862) with videos related to

Sort By:
Pageof 87
Hypertension (Dallas, Tex. : 1979)|December 28, 2017
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing AdenomaBritta Heinze, Carmina T Fuss, Paolo Mulatero, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
EMBO Molecular Medicine|March 5, 2015
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myelomaKathrin Philipp-Abbrederis, Ken Herrmann, Stefan Knop, et al.
ESC Heart Failure|July 15, 2022
Peak O<sub>2</sub> -pulse predicts exercise training-induced changes in peak V̇O<sub>2</sub> in heart failure with preserved ejection fractionStephan Mueller, Bernhard Haller, Anna Feuerstein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasmsBrady L Stein, Jason Gotlib, Murat Arcasoy, et al.
Science Translational Medicine|December 6, 2023
Intervertebral disc human nucleus pulposus cells associated with back pain trigger neurite outgrowth in vitro and pain behaviors in ratsWensen Jiang, Juliane D Glaeser, Giselle Kaneda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2022
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with GuadecitabineCasey L O'Connell, Maria R Baer, Andreas Due Ørskov, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)ValidationJulie Farand, Jeffrey E Kropf, Peter Blomgren, et al.
Pageof 87